Is Technology Impacting Hospital Negligence Cases?

While the overwhelming majority of medical treatment in the UK is dispensed without a problem, a minority amount to clinical negligence. In 2020/21, a total of 12,629 claims of clinical negligence were made against the NHS. As such, this is a significant problem. But precisely what measures might be employed to drag these figures down?

Part of the solution is likely to come from the world of technology, which can not only improve the quality of clinical care, but improve its efficiency, too. Patients might be seen more quickly, and given more effective treatments.

How technology is impacting medical negligence

There are a number of powerful ways in which the right tech might make our medical institutions more powerful. One particularly promising example is the use of artificial intelligence to examine images from patients, and detect cancers with a greater degree of accuracy than human radiographers. This is done using something called ‘swarm learning’, which is a form of machine learning which uses the aggregate of several different machine-learning intelligences, created separately at different hospitals using different data.

Naturally, in the case of cancers, early intervention tends to be significant in ensuring a positive outcome. Many clinical negligence claims centre around conditions like this being misdiagnosed, and harm being suffered as a result of the subsequent delay in administering treatment. This kind of step forward might therefore help to drive down the overall rate of medical negligence.

As well as diagnosis and treatment, technology might also help with administration – which ultimately plays a significant role in how quickly and accurately the eventual treatments are. Many cases of negligence result from miscommunication between medical professionals. Solid, reliable record-keeping software might help to avoid this problem.

The Rise of IoT and wearables

Another encouraging development is the proliferation of wearable technology among the general public. Smartwatches, like the Apple Watch 8, are able to continuously monitor a whole range of metrics. These include things like heart rate, blood oxygen level, and general activity. They can allow individuals to make better decisions about their personal fitness, which ultimately means better health outcomes and less opportunity for hospital negligence.

The data transmitted by wearable devices might also inform decisions when it comes to care. This reduces the scope for mistakes – provided that any flaws in the data are accounted for. We should attach a few caveats, however; wearable devices are expensive, and out of the reach of many. The rich, in other words, will reap the benefits of this particular advantage long before the poor do. It will take several years before the technology becomes viable and affordable for everyone.

With that said, we might have once said the same thing about smartphones, which are now ubiquitous at every level. It might be in the future that everyone has access to a continual ECG reading.

The use of AI

We’ve already touched upon one potential use of artificial intelligence, in radiography. But that’s just the tip of the iceberg. AI is also being used extensively by the pharmaceutical industry, in the development of new and more effective drugs and diagnostic processes. Artificial intelligence isn’t just being used to supplant and supplement human intelligence; it’s also being used to perform tasks that no human being can perform, like scouring through huge amounts of biochemical data, and arriving at novel solutions which might otherwise have proven elusive.

Augmented reality

Virtual reality is the practice of swapping the real world out for a fake one. It’s done using the help of a virtual-reality headset. Augmented reality is close to the same thing, except rather than replacing the real world, it supplements it. In a medical context, this is especially useful in the world of surgery, where surgeons might have access to important pieces of information while keeping their hands free. It might also be used for training purposes, helping new recruits to improve their competencies. In both cases, the ultimate rate of failure would be driven down.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

“The completion of the APEX-AV Study represents an important milestone in the catheter-directed therapies CDT space for the treatment of pulmonary embolism. I sincerely thank all the investigators for their commitment and dedication,” said William Brent Keeling, MD, Associate Professor of Surgery, Department of Surgery, at the Emory University School of Medicine, and Immediate Past President, The PERT Consortium™.
The combined expertise of Cordance Medical and the Airan and Williams Labs will see NeuroAccess utilized to deliver a novel application of drug-loaded nanoparticles, providing targeted drug delivery to the brain.
Medixine prepares for 2024 with two key senior hires, VP of Operations in the U.S. and VP of Engineering in Finland. The appointments will enhance support and service to the company’s U.S.-based partners, including leading respiratory homecare provider Lincare and a major medical device manufacturer. In addition, the new hires will enable streamlined design, testing, and deployment of new product features for more patient-centric, cost and time-effective treatment of chronic conditions.
Innovent Biologics and Synaffix: Under the terms of the expanded agreement, Innovent will be responsible for the research, development, manufacturing and commercialization of new ADC candidates. Synaffix is eligible to receive an upfront payment plus potentialmilestone payments and royalties on commercial sales for each licensed target.
Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.

By using this website you agree to accept Medical Device News Magazine Privacy Policy